

1 **Surveying the landscape of tRNA modifications by combining**
2 **tRNA sequencing and RNA mass spectrometry**

3
4 Satoshi Kimura^{1,2,3*}, Peter C. Dedon^{4,5} and Matthew K. Waldor^{1,2,3*}

5
6 ¹Division of Infectious Diseases, Brigham and Women's Hospital

7 ²Department of Microbiology, Harvard Medical School

8 ³Howard Hughes Medical Institute

9 ⁴Department of Biological Engineering, Massachusetts Institution of Technology

10 ⁵Singapore-MIT Alliance for Research and Technology Antimicrobial Resistance
11 Interdisciplinary Research Group

12

13

14 For correspondence: s.kimura.res@gmail.com or mwaldor@research.bwh.harvard.edu

15 **Abstract**

16 Chemical modification of the nucleosides that comprise tRNAs are diverse¹⁻³. Such modifications impact
17 tRNA structure, stability, and mRNA decoding^{3,4}. Although tRNA modifications are present in all
18 kingdoms of life¹, the structure, location, and extent of modifications have been systematically charted
19 in very few organisms, in part because mapping modifications to tRNA sequences has been technically
20 challenging. Here, we describe a new approach in which rapid prediction of modified sites through
21 reverse transcription-derived signatures in high-throughput tRNA-sequencing (tRNA-seq) data is
22 coupled with chemical analysis and identification of tRNA modifications through RNA mass
23 spectrometry (tRNA-SMS). As proof of concept, we applied this method to study tRNA modification
24 profiles in two phylogenetically close bacteria, *E. coli* and *Vibrio cholerae*. Comparative tRNA-seq
25 enabled prediction of several *V. cholerae* modifications that are absent from *E. coli* and showed the
26 effects of various environmental conditions on *V. cholerae* tRNA modification profiles. Through RNA
27 mass spectrometric analyses, we showed that two of the *V. cholerae*-specific reverse transcription
28 signatures reflected the presence of a new modification (acetylated acp³U (acacp³U)), while another
29 results from C-to-U RNA editing, a process not described before in bacteria. By combining comparative
30 genomics with mass spectrometry, we identified a putative N- acetyltransferase required for acacp³U
31 acetylation. These findings demonstrate the utility of the tRNA-SMS approach for rapid characterization
32 of tRNA modification profiles and environmental control of tRNA modification. Moreover, our
33 identification of a new modified nucleoside and RNA editing process suggests that there are many tRNA
34 modifications awaiting discovery.

35 Several methods have been developed to predict the presence of modified sites from deep
36 sequencing data of tRNAs^{5,6}. To verify that deep sequencing of tRNAs (tRNA-seq) can predict the
37 presence of tRNA modifications through detection of misincorporated nucleosides or premature
38 termination of reverse transcription, we conducted deep-sequencing of purified total tRNA from *E. coli*,
39 where the sites and chemical nature of tRNA modifications have been elucidated⁷. The sequencing
40 library was constructed using a modified version of a published protocol⁶ (Supplementary Fig. 1). Reads
41 were mapped to reference *E. coli* tRNA genes and pile up files for each locus were generated (e.g.,
42 Supplementary Fig. 2A). As expected, we observed a drop in mapped read depth and/or incorporation
43 of mismatched bases at known modified residues (e.g., s⁴U at position 8, D at 16 and 17, mnm⁵s²U at 34
44 and acp³U at 47; Supplementary Fig. 2A). Heatmaps depicting the frequency of misincorporation and
45 ratio of termination throughout all tRNAs were generated (Supplementary Fig. 2B). In total, more than
46 half of known modifications were detected in the sequencing of *E. coli* tRNA (16 out of 28)
47 (Supplementary Fig. 2B, Supplementary Table 1, Supplementary Data 1, and see Methods). Thus, RT-
48 derived signatures can be used to profile many tRNA modifications.

49 Next, we applied tRNA-seq to define tRNA modification profiles in an organism where tRNA
50 modifications have not been characterized: *Vibrio cholerae*, the cholera pathogen. Analysis of tRNA-seq
51 data from stationary phase *V. cholerae* samples yielded heatmaps of misincorporation and termination
52 similar to those of *E. coli* (Fig. 1). This observation is consistent with the conservation of most *E. coli*
53 tRNA modification enzymes in *V. cholerae* (Supplementary Data 2). The identity of modifications
54 introduced by *thiI*, *ttcA*, and *miaA* (s⁴U, s²C, and ms²io⁶A, respectively) was confirmed by analyzing tRNA
55 from strains lacking these enzymes (Supplementary Fig. 3A-C).

56 We observed several misincorporation signals in *V. cholerae* that were not present in *E. coli*,
57 including at A22 and C32 in tRNA-Tyr, U20B in tRNA-Glu, U46 in tRNA-Gln1A, Gln1B and Gln1C, G6 in
58 tRNA-Leu1B, C35 in tRNA-Arg2A and A63 in tRNA-fMetC (Fig. 1). U20B in tRNA-Glu and U46 in tRNA-
59 Gln1ABC were also associated with increased termination of reverse transcription (Fig. 1). In other
60 bacteria, e.g., *B. subtilis*, A22 is methylated to m¹A by TrmK in a subset of tRNAs^{7,8}; consequently, we
61 explored the effect of *V. cholerae*'s TrmK homolog on misincorporation at A22 in tRNA-Tyr. A *V. cholerae*
62 *trmK* deletion mutant lacked the misincorporation signal at A22 in tRNA-Tyr, suggesting that *V.*
63 *cholerae* contains m¹A in tRNA-Tyr (Supplementary Fig. 3D).

64 The variation of modification profiles of individual tRNAs in log and stationary phase bacteria have
65 not been systematically characterized. Comparisons of tRNA-seq patterns of samples derived from log
66 and stationary phase *V. cholerae* cultures (Fig. 1A and Supplementary Fig. 4A) revealed a significantly
67 higher misincorporation frequency at position 47 in a subset of log phase tRNAs (e.g., tRNA-Met), which
68 presumably contain acp³U (Fig. 2A). Mass spectrometric analysis of purified tRNA-Met fragments
69 confirmed that this modification is present at this site and is more prevalent in the log phase sample
70 (Fig. 2B, C and Supplementary Fig. 5). Interestingly, in *E. coli*, misincorporation frequency at position 47
71 was higher in stationary phase (Fig. 2D), suggesting that there are species-specific mechanisms for
72 control of modification frequency. We also determined the tRNA-seq profiles of *V. cholerae* tRNA

73 samples derived from the cecal fluid of infant rabbits infected with the pathogen⁹. The resulting
74 misincorporation and termination signatures were similar to those of log phase samples
75 (Supplementary Fig. 4B vs. 4A), including modification at position 47 (Fig. 2A). Thus, tRNA-seq enables
76 assessment of tRNA modification profiles under a variety of conditions.

77 We hypothesized that RT signatures found in *V. cholerae* but not *E. coli* (Fig. 1AB) could reflect *V.*
78 *cholerae*-specific modifications, and used RNA mass spectrometric analysis to identify the chemical
79 moieties at some of these positions, focusing initially on U20B in tRNA-Glu and U46 in tRNA-Gln1B.
80 Nucleoside analyses, which reveal the composition of modified ribonucleosides in each tRNA, were
81 carried out on purified tRNA-Glu and tRNA-Gln1B, and revealed that tRNA-Glu contains Ψ , mnm⁵s²U, T
82 and Gm, while tRNA-Gln1B contains D, Ψ , cmnm⁵s²U, T, s⁴U and m²A (Supplementary Fig. 3A and
83 Supplementary Data 3). In addition, these analyses showed that tRNA-Glu and tRNA-Gln1B both also
84 possesses a ribonucleoside whose molecular weight is 387 (Fig. 3A, Supplementary Fig. 6). Since no
85 known modified ribonucleoside has a mass of 387², we postulated that this nucleoside (designated
86 N387) is a novel modification that may be incorporated at various sites (e.g., U20B or U46) within
87 tRNAs. To confirm the positions of N387, we performed fragment analyses. N387-containing fragments
88 were detected using MALDI-TOF mass spectrometry of tRNAs digested with RNase A, which cleaves at
89 the 3' end of C and U, or RNase T₁, which cleaves at the 3' end of G (Fig. 3A and Supplementary Fig. 7).
90 RNase A digests revealed fragments of m/z 2121.7 in tRNA-Glu and 1431.1 in tRNA-Gln1B, consistent
91 with the location of N387 at U20B and U46 in these tRNAs, respectively (Fig. 3A). These results suggest
92 that the *V. cholerae*-specific misincorporation signals in tRNA-Glu and tRNA-Gln1B result from N387.

93 High-resolution mass spectrometric analysis of N387 from tRNA-Glu yielded a mass value of
94 387.1273; the best matched chemical formula¹⁰ corresponding to this mass value is C₁₅H₂₁N₃O₉ (Fig.
95 3B). This formula is close to that of acp³U (C₁₃H₁₉N₃O₈), with the difference in chemical composition
96 between these compounds corresponding to acetylation (C₂H₂O). Since acp³U contains a primary
97 amine, a plausible target of acetylation, we predicted that N387 is acetylated acp³U, i.e., 3-(3-
98 acetamidocarboxypropyl)uridine (acacp³U). MS/MS analysis with acp³U and N387 was used to test this
99 hypothesis. The product ions of acp³U, e.g., m/z 56, 168 and 214, were also observed in the spectrum of
100 N387, consistent with the presence of acp³U in the structure of N387 (Fig. 3C). Several additional
101 fragment ions (e.g., m/z 238 and 210) further corroborate the proposed structure of N387 as acacp³U.
102 MS/MS spectra of N387 were nearly identical in tRNA-Gln1A and tRNA-Gln1B (Supplementary Fig. 8),
103 suggesting that these tRNAs also contain acacp³U.

104 A comparative genomics approach was then used to identify an acetyltransferase that is required
105 for acacp³U formation. We analyzed total tRNA from bacterial species that are phylogenetically close to
106 *V. cholerae* (*Vibrio parahaemolyticus*, *Aeromonas hydrophila*, and *Shewanella oneidensis*), and found that
107 *V. parahaemolyticus* contains acacp³U but the other bacteria do not (Fig. 3D and Supplementary Fig. 9).
108 Based on these results and our *E. coli* data, we identified candidate acetyltransferases in *V. cholerae* (Fig.
109 3D and Supplementary Data 4). Of the 47 genes annotated as acetyltransferases in the COG database¹¹,
110 only 5 are present in *V. cholerae* and *V. parahaemolyticus* but absent in *A. hydrophila*, *S. oneidensis* and *E.*

111 *coli* (Fig. 3D and Supplementary Data 4). Nucleoside analysis of total tRNA from transposon insertion
112 mutants corresponding to each of these 5 loci¹² detected a decreased acacp³U signal and an increased
113 acp³U signal in tRNA from *vc0317::Tn* (Supplementary Fig. 10). Furthermore, analysis of tRNA from an
114 in-frame *vc0317* deletion mutant revealed that disruption of *vc0317* abolished the acacp³U signal and
115 increased the acp³U signal (Fig. 3E). Collectively, these results strongly suggest that *vc0317* mediates
116 acetylation during acacp³U synthesis and we renamed *vc0317* as *acpA* (for acp³U acetylation). Notably
117 in PFAM¹³, *acpA* is predicted to encode an *N*-acetyltransferase, providing further support for the idea
118 that N387 includes acetylation of a primary amine group. One effect of acetylation of acp³U involves
119 tRNA abundance, with modestly reduced tRNA-Gln1A levels in log phase cultures of Δ *acpA* compared to
120 the wild type strain (Fig. 3F).

121 *V. cholerae* tRNA-seq analysis also revealed a high misincorporation frequency at C32 in tRNA-Tyr
122 (Fig. 1A). Most sequencing reads contained U rather than C at position 32, even though C is present in
123 all 5 copies of this tRNA gene¹⁴ (Supplementary Fig. 11). RT-PCR coupled with direct Sanger sequencing
124 confirmed the presence of this C-to-U conversion in tRNA-Tyr (Fig. 4A). However, ribonucleoside and
125 fragment analysis of purified tRNA-Tyr did not detect any modifications that could be assigned to
126 position 32, although it successfully assigned several other modifications (Fig. 4B, Supplementary Fig.
127 12). Instead, fragment analysis revealed a U32-containing fragment (AGAU_p, *m/z* 1326.25) (Fig. 4C),
128 strongly suggesting that C32 undergoes post-transcriptional C-to-U RNA editing. Intriguingly, tRNA-Tyr
129 from a strain lacking *miaA*, which is responsible for the initial step of biosynthesis of ms²io⁶A at position
130 37 in tRNA-Tyr, retains C at position 32 (Fig. 4AC). tRNA-Tyr from a strain lacking *thiI*, whose product
131 synthesizes s⁴U at position 8 and 9 in tRNA-Tyr, contained both C and U at position 32 (Fig. 4A). These
132 results suggest that C-to-U editing at this site depends upon the presence of other modification(s) or the
133 associated modification enzymes. The enzyme responsible for C-to-U RNA editing in *V. cholerae* remains
134 unknown. Since *T. brucei*'s A-to-I editing enzyme is reported to catalyze C-to-U editing as well¹⁵, it is
135 possible that VC0864, *V. cholerae*'s presumed A-to-I tRNA editing enzyme, could also be involved in C-
136 to-U editing

137 Our findings demonstrate that comparative tRNA-seq provides a high-throughput method for
138 cataloging sites of likely tRNA modification and identifying tRNA species or conditions warranting more
139 in-depth analyses. By combining tRNA-seq and RNA mass spectrometry (tRNA-SMS) to characterize *V.*
140 *cholerae*'s tRNA, we uncovered a species-specific modification (m¹A) and discovered a new tRNA
141 modification (acacp³U) along with an enzyme required for its synthesis. Moreover, this approach
142 yielded evidence of C-to-U RNA editing, a process not previously observed in bacteria. Thus, our data
143 reveals substantial diversity in tRNA modifications among even phylogenetically closely related
144 organisms like *V. cholerae* and *E. coli*. Since the full complement of tRNA modifications have been well
145 characterized in only a few model organisms, e.g., *E. coli* and *Saccharomyces cerevisiae*, it is likely that
146 there is a plethora of as yet undescribed modifications. The tRNA-SMS approach should be useful to
147 probe the diversity of tRNA modifications throughout all three kingdoms of life.

148 **Methods**

149 **Strains and culture conditions**

150 The strains used in this study are listed in Supplementary Table 2. *V. cholerae* C6706, a clinical
151 isolate¹⁶, and *E. coli* MG1655 were used in this study as wild-type strains. All *V. cholerae*, *E. coli*, and *V.*
152 *parahaemolyticus* strains were grown in LB containing 1 % NaCl at 37 °C. *E. coli* SM10 (lambda pir)
153 harboring derivatives of pCVD442¹⁷ was cultured in LB plus carbenicillin (Cb). Antibiotics were used at
154 the following concentrations: 200 µg/mL streptomycin, 50 µg/mL Cb. *Aeromonas hydrophila* and
155 *Shewanella oneidensis* were cultured at 30°C in nutrient broth (BD) and Tryptic Soy Broth, respectively.

157 **Strain construction**

158 All mutations in C6706 were created using homologous recombination and a derivative of the
159 suicide vector pCVD442¹⁷. Targeting vectors for gene deletions contained ~1000 bp of DNA flanking
160 each side of the target gene cloned into pCVD442's SmaI site using isothermal assembly.

162 **RNA extraction**

163 Total RNA was extracted with TRIzol (Life Technologies) according to the manufacturer's
164 instructions. The tRNA fraction was cut out from 10 % TBE-Urea gels and recovered by isopropanol
165 precipitation.

167 **Isolation of individual tRNA species**

168 One liter cultures of log-phase ($OD_{600} = 0.3$) and stationary phase (24h) *V. cholerae* cells were
169 harvested, and total RNA was extracted¹⁸. Briefly, cells were resuspended in 5 mL buffer [50 mM
170 NaOAc, pH 5.2, 10 mM Mg(OAc)₂], mixed with 5 mL water saturated phenol, and agitated vigorously for
171 1 h. The aqueous phase was separated by centrifugation, washed with chloroform, and recovered by
172 isopropanol precipitation. RNA was run through a manually packed DEAE column (GE healthcare) to
173 remove contaminants and recovered by isopropanol precipitation. Individual tRNA species were bound
174 to biotinylated DNA probes anchored to high-capacity streptavidin agarose resin (GE Healthcare) in 30
175 mM Hepes-KOG, pH 7.0, 1.2 M NaCl, 15 mM EDTA, and 1 mM DTT at 68 °C for 30 min with shaking.
176 Beads were washed three times with 15 mM Hepes-KOH, pH 7.0, 0.6 M NaCl, 7.5 mM EDTA, and 1 mM
177 DTT and seven times with 0.5 mM Hepes-KOH, pH 7.0, 20 mM NaCl, 0.25 mM EDTA, and 1 mM DTT.
178 Purified tRNAs were extracted from beads with TRIzol. After Turbo DNase (Thermo Fisher Scientific)
179 treatment to remove residual DNA probes, purified tRNAs were purified on 10 % TBE-Urea gels. The
180 probes used in this study are listed in Supplementary Data 5.

183 **tRNA sequencing**

184 Total tRNA fraction (250 ng) was deacylated in 500 µl of 100 mM Tris-HCl pH 9.0 at 37 °C for 1 hr
185 and recovered by isopropanol precipitation. After dephosphorylation with alkaline phosphatase from

186 calf intestine (New England Biolabs), tRNAs were ligated to 100 pmol of 5' adenylated and 3' end-
187 blocked DNA oligo (3' linker, Supplementary Data 5) using truncated T4 RNA ligase at 25 °C for 2.5 hr in
188 25 % PEG 8000. The ligated product was purified on a 10 % TBE-Urea polyacrylamide gel (Thermo
189 Fisher Scientific) as above. Half of the recovered ligated tRNAs were reverse transcribed with 5 pmol
190 TGIRT-III (InGex) in 100 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 450 mM NaCl, 5 mM MgCl₂, 5 mM DTT, 1
191 mM dNTPs, and 1.25 pmol primer (ocj485, Supplementary Data 5) at 60 °C for 1 hr. After the
192 elimination of template RNAs by alkali treatment, cDNA was purified on a 10 % TBE-Urea
193 polyacrylamide gel. The single stranded cDNA was then circularized using 50 U of CircLigase
194 II(Epicenter) at 60 °C for 1 hr, followed by addition of another 50 U of CircLigase II for an additional 1
195 hr at 60 °C. cDNA was amplified using Phusion DNA polymerase (New England Biolabs) with o231
196 primer and index primers (Supplementary Table S2). After 12-18 rounds of PCR amplification, the
197 product was gel purified from an 8 % TBE-Urea polyacrylamide gel (Thermo Fisher Scientific).
198 Sequencing was performed using a Illumina miSeq. 3' linker sequences and one nucleotide at the 5' end
199 was trimmed. Bowtie¹⁹ v. 1.2.2 with default settings was used for mapping reads to reference tRNA
200 sequences (Supplementary Data 6) retrieved from tRNADB⁷. Two sequences in *V. cholerae*
201 (tdbD00003706, tdbD00008082) and three sequences in *E. coli* (tdbD00007320, tdbD00010329, and
202 tdbD00011810) were eliminated from the reference sequences due to extremely low coverage. Mpileup
203 files were made using the samtools mpileup command without any filtration (option, -A -ff 4 -x -B -q 0 -
204 d 10000000 -f). The frequency of misincorporation was calculated in each mpileup file. 5' end termini of
205 the mapped reads were piled up using the bedtools genomecov command (-d -5 -ibam). To calculate the
206 termination frequency, the number of 5' termini at any given position was divided by the total number
207 of mapped termini at the given position along with all upstream positions (5' side). Frequencies of
208 misincorporation and termination of one replicate were visualized with R (3.4.3) or Graphpad Prism.

209 Reference sequences of *E. coli* tRNAs along with the catalogue of modifications in the tRNA
210 database and the literature^{7,20-27} (Supplementary Data 1 and Supplementary Table 1) were used to
211 assign modifications to the *E. coli* tRNA-seq data in Supplementary Figure 2. Misincorporation
212 frequencies of > 5% at sites of modification in the reference database were used as a threshold for
213 assignment of predicted modifications. Termination frequencies of >5% were also used as a threshold
214 for assignments of modified sites; however, since termination signals were usually detected two
215 nucleotides downstream from known modified sites, assignments were adjusted accordingly (except
216 for DD, acp³U, k²C, and m⁶t⁶A (see Supplementary Table 1)). *E. coli* modifications were considered to be
217 predictable when signals (either of misincorporation or termination) were present in ≥ 50% of known
218 modified sites.

219 *V. cholerae* modifications were also assigned with >5% thresholds for misincorporation or
220 termination. Although G at position 10 (G10) in several tRNAs and G at position 35 (G35) in tRNA-Leu2
221 have misincorporation signals greater than 5%, they were excluded from further analysis because these
222 signals were also observed in the *E. coli* data, where G10 and G35 modifications have not been reported.

223 These elevated misincorporation signals may arise from other factors including residual secondary or
224 tertiary structures or specific sequence contexts influencing reverse transcription.

225

226 **Northern blotting**

227 In total, 0.3 µg RNA was electrophoresed on 10 % Novex TBE-Urea gels (ThermoFisher) and stained
228 with SYBR Gold (Life Technologies). RNA was transferred to nitrocellulose membranes by semidry
229 blotting and cross-linked twice to membranes with 1200 µJ UV light. Membranes were incubated in
230 ULTRAhyb-oligo (Life Technologies) at 42 °C for 30 min followed by hybridization overnight at 42 °C
231 with 4 pmol DNA probes radiolabeled with [γ -³²P]ATP (PerkinElmer) and T4 Polynucleotide kinase
232 (New England Biolabs). Membranes were washed twice with 2 × SSC/0.5 % SDS, and then bound probe
233 was detected using an FLA-5000 phosphorimager (Fuji). The signal intensity of tRNA was normalized to
234 that of 5S rRNA. All DNA oligos were synthesized by Integrated DNA Technology. Probe sequences are
235 listed in Supplementary Data 5.

236

237 **Nucleoside analysis**

238 100 ng of total RNAs or isolated tRNAs were digested with 0.5 unit Nuclease P1 and 0.1 unit of
239 phosphodiesterase I in 22 µl reactions containing 50 mM Tris-HCl pH 5.3, 10 mM ZnCl₂ at 37 °C for 1 h.
240 Reaction mixtures were then mixed with 2 µl 1M Tris-HCl pH 8.3 and 1 µl of 1 unit/µl Calf Intestine
241 phosphatase and incubated at 37 °C for 30 min. Enzymes were removed by filtration using 10 K
242 ultrafiltration columns (VWR). 18 µl aliquots were mixed with 2 µl of 50 µM ¹⁵N-dA and 2.5-10 µl of
243 digests were injected into a Agilent 1290 uHPLC system bearing a Synergi Fusion-RP column (100 × 2
244 mm, 2.5 µm, Phenomenex) at 35 °C with a flow rate 0.35 ml/min with a solvent system consisting of 5
245 mM NH₄OAc (Buffer A) and 100 % Acetonitrile (Buffer B). The gradient of acetonitrile was as follows:
246 0 %; 0-1 min, 0-10 %; 1-10 min, 10-40 %; 10-14 min, 40-80 %; 14-15 min, 80-100 %; 15-15.1 min,
247 100 %; 15.1-18 min, 100-0 %; 18-20 min, 0 %; 20-26 min. The eluent was ionized by an ESI source and
248 directly injected into a Agilent 6460 QQQ. The voltages and source gas parameters were as follows: gas
249 temperature; 250 °C, gas flow; 11 L/min, nebulizer; 20 psi, sheath gas temperature; 300 °C, sheath gas
250 flow; 12 L/min, capillary voltage; 1800 V, and nozzle voltage; 2000 V.

251 Dynamic multiple reaction monitoring (MRM) was carried out to survey known modifications. In
252 the first quadrupole, a proton adduct of a target nucleoside was selected as a precursor ion based on its
253 mass to charge ratio (m/z). Only singly charged ions, i.e., z equals 1, were observed. In the second
254 quadrupole, the precursor was broken by collision inducible dissociation (CID) to produce nucleoside
255 species specific product ions, which in many cases were proton adducts of different bases. Then, one
256 specific product ion was selected in the third quadrupole based on its m/z value and delivered to the
257 detector. This multiple selection approach, with targeting of specific precursor and product ions,
258 enables high signal to noise ratios. The retention time windows and m/z values of precursor and
259 product ions for dynamic MRM analyses are listed in Supplementary Data 3.

260 The neutral loss scan (NLS) method was used to search for unknown modifications. For one run,
261 we used ~50 mass values of precursor ions with 1 Da intervals. Then, a mass of the product ion was set
262 132 Da lower than that of the precursor ion, a value corresponding to the loss of a ribose moiety. We
263 performed five runs to cover precursor ions whose m/z values ranged from 244 to 445 (Supplementary
264 Fig. 6). The presence of N387 was then confirmed by MRM analysis.

265 For MS/MS analysis, 1 μg of isolated tRNAs were hydrolyzed. In this analysis, we selected singly-
266 protonated ions with m/z 388 for N387 and 346 for acp³U as precursor ions in the first quadrupole,
267 respectively; after CID in the second quadrupole, an m/z scan from 10 to 1000 was carried out in the
268 third quadrupole, yielding the mass spectra of the fragments.

269 To measure the mass of N387 precisely, 2.5 μg of tRNA-Glu was digested as described above and
270 500 ng of the digest was subjected to the HPLC system described above coupled with an Agilent 6520
271 quadrupole time-of-flight (QTOF) mass spectrometer. An offset value that is an average error ppm value
272 of 5.9 ppm in known nucleosides (including A, G, Gm, mnm⁵s²U, and m²A), was added to the measured
273 mass value (387.1251) to obtain the calibrated mass value of N387 (387.1274). The chemical formula
274 was explored in ChemCalc Molecular Formula Finder¹⁰ with the following constraints: C,9-100, H,0-100,
275 N,2-10, O,5-10, S,0-3, unsaturation,3-8, with restriction to integral unsaturation values.

276

277 **Fragment analysis**

278 400-1000 ng isolated tRNAs were digested in 3 μl aliquot with 20 ng RNase A (QIAGEN) in 10 mM
279 NH₄OAc pH 7 or 20 unit RNase T₁ in 10 mM NH₄OAc pH 5.3 at 37 °C for 1 hr. On a MALDI steel plate, 0.5
280 μl of matrix (0.7 M 3-hydroxypicolinic acid (HPA) and 70 mM ammonium citrate in 50 % milliQ and
281 50 % acetonitrile) was mounted and dried, followed by mounting of 0.5 μl RNase digests and drying.
282 The samples were analyzed with Bruker Ultraflex Xtreme MALDI-TOF mass spectrometer.

283

284 **Oligo protection**

285 2.8 and 3.8 μg of tRNA-Tyr from WT and $\Delta miaA$ were mixed with 500 pmol of DNA oligos
286 (Supplementary Data 5) in 50 μl aliquots containing 50 mM Hepes KOH pH 7.6, 150 mM KCl and heated
287 to 90 °C for 1 min and gradually cooled down to room temperature at 1 °C/min for annealing, followed
288 by RNase digestion with 50 ng RNase A and 50 unit RNase T₁ on ice for 15 min. Protected DNA/RNA
289 duplexes were purified on 10 % TBE-Urea gels and recovered by isopropanol precipitation and dissolved
290 in 5 μl milliQ. A 2 μl aliquot was subjected to fragment analysis with RNase A using a MALDI-TOF
291 spectrometer as described above.

292

293 **Comparative genomics**

294 Protein sequences were retrieved from NCBI (*V. cholerae*; GCF_000006745.1, *V. parahaemolyticus*;
295 GCF_000196095, *E. coli*; GCF_000005845.2, *S. oneidenis*; GCF_000146165.2, and *A. hydrophila*;
296 GCF_000014805.1). The *V. cholerae* protein sequences were queried with the other species' protein
297 sequences with local BLAST and an E-value threshold of 1E-10 to identify similar sequences. Forty

298 seven *V. cholerae* proteins that include “acetyltransferase” in their COG names were retrieved from COG
299 2003-2014 update using R¹¹. Five of these putative acetyltransferases were found to be present in *V.*
300 *cholerae* and *V. parahaemolyticus*, but not in *A. hydrophila*, *S. oneidenis* and *E. coli* when 1E-10 was used
301 as a threshold.

302

303 **Infant rabbit infection**

304 Mixed-gender litters of 2 day old New Zealand white infant rabbits, cohoused with a lactating
305 mother (Charles River) were inoculated with wild-type *V. cholerae* as described⁹. Approximately 20hr
306 post-inoculation, the rabbits were sacrificed and *V. cholerae* in the cecal fluid was collected by
307 centrifugation. Total RNA was then extracted using TRIzol reagent.

308

309 **Animal use statement**

310 Infant rabbit studies were conducted according to protocols approved by the Brigham and Women’s
311 Hospital Committee on Animals (Institutional Animal Care and Use Committee protocol number
312 2016N000334 and Animal Welfare Assurance of Compliance number A4752-01) and in accordance
313 with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National
314 Institutes of Health and the Animal Welfare Act of the U.S. Department of Agriculture.

315

316 **Data availability**

317 All data is available from the corresponding authors upon request.

318

319 **Code availability**

320 All codes are available from the corresponding authors upon request.

321

322 **Competing interests**

323 The authors declare no competing interests.

324

325 **Acknowledgments**


326 We thank Brigid Davis, Troy Hubbard and Waldor lab members for helpful comments on the project
327 and the manuscript, and the Harvard FAS Science Core Facility for use of MALDI equipment. This work
328 was supported by NIH R01-AI-042347 and HHMI (MKW)

329

330 References

- 331 1 Cantara, W. A. *et al.* The RNA Modification Database, RNAMDB: 2011 update. *Nucleic Acids Res* **39**, D195-
332 201, doi:10.1093/nar/gkq1028 (2011).
- 333 2 Machnicka, M. A. *et al.* MODOMICS: a database of RNA modification pathways--2013 update. *Nucleic Acids*
334 *Res* **41**, D262-267, doi:10.1093/nar/gks1007 (2013).
- 335 3 Ontiveros, R. J., Stoute, J. & Liu, K. F. The chemical diversity of RNA modifications. *Biochem J* **476**, 1227-
336 1245, doi:10.1042/BCJ20180445 (2019).
- 337 4 Bjork, G. R. & Hagervall, T. G. Transfer RNA Modification: Presence, Synthesis, and Function. *EcoSal Plus* **6**,
338 doi:10.1128/ecosalplus.ESP-0007-2013 (2014).
- 339 5 Cozen, A. E. *et al.* ARM-seq: AlkB-facilitated RNA methylation sequencing reveals a complex landscape of
340 modified tRNA fragments. *Nat Methods* **12**, 879-884, doi:10.1038/nmeth.3508 (2015).
- 341 6 Zheng, G. *et al.* Efficient and quantitative high-throughput tRNA sequencing. *Nat Methods* **12**, 835-837,
342 doi:10.1038/nmeth.3478 (2015).
- 343 7 Juhling, F. *et al.* tRNADB 2009: compilation of tRNA sequences and tRNA genes. *Nucleic Acids Res* **37**, D159-
344 162, doi:10.1093/nar/gkn772 (2009).
- 345 8 Roovers, M. *et al.* The YqfN protein of *Bacillus subtilis* is the tRNA: m1A22 methyltransferase (TrmK).
346 *Nucleic Acids Res* **36**, 3252-3262, doi:10.1093/nar/gkn169 (2008).
- 347 9 Ritchie, J. M., Rui, H., Bronson, R. T. & Waldor, M. K. Back to the future: studying cholera pathogenesis using
348 infant rabbits. *MBio* **1**, doi:10.1128/mBio.00047-10 (2010).
- 349 10 Patiny, L. & Borel, A. ChemCalc: a building block for tomorrow's chemical infrastructure. *J Chem Inf Model*
350 **53**, 1223-1228, doi:10.1021/ci300563h (2013).
- 351 11 Galperin, M. Y., Makarova, K. S., Wolf, Y. I. & Koonin, E. V. Expanded microbial genome coverage and
352 improved protein family annotation in the COG database. *Nucleic Acids Res* **43**, D261-269,
353 doi:10.1093/nar/gku1223 (2015).
- 354 12 Cameron, D. E., Urbach, J. M. & Mekalanos, J. J. A defined transposon mutant library and its use in
355 identifying motility genes in *Vibrio cholerae*. *Proc Natl Acad Sci U S A* **105**, 8736-8741,
356 doi:10.1073/pnas.0803281105 (2008).
- 357 13 Finn, R. D. *et al.* The Pfam protein families database: towards a more sustainable future. *Nucleic Acids Res*
358 **44**, D279-285, doi:10.1093/nar/gkv1344 (2016).
- 359 14 Chan, P. P. & Lowe, T. M. GtRNADB 2.0: an expanded database of transfer RNA genes identified in complete
360 and draft genomes. *Nucleic Acids Res* **44**, D184-189, doi:10.1093/nar/gkv1309 (2016).
- 361 15 Rubio, M. A. *et al.* Editing and methylation at a single site by functionally interdependent activities. *Nature*
362 **542**, 494-497, doi:10.1038/nature21396 (2017).
- 363 16 Millet, Y. A. *et al.* Insights into *Vibrio cholerae* intestinal colonization from monitoring fluorescently
364 labeled bacteria. *PLoS Pathog* **10**, e1004405, doi:10.1371/journal.ppat.1004405 (2014).
- 365 17 Donnenberg, M. S. & Kaper, J. B. Construction of an eae deletion mutant of enteropathogenic *Escherichia*
366 *coli* by using a positive-selection suicide vector. *Infect Immun* **59**, 4310-4317 (1991).

- 367 18 Kimura, S. & Waldor, M. K. The RNA degradosome promotes tRNA quality control through clearance of
368 hypomodified tRNA. *Proc Natl Acad Sci U S A* **116**, 1394-1403, doi:10.1073/pnas.1814130116 (2019).
- 369 19 Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA
370 sequences to the human genome. *Genome Biol* **10**, R25, doi:10.1186/gb-2009-10-3-r25 (2009).
- 371 20 Griffey, R. H. *et al.* 15N-labeled tRNA. Identification of 4-thiouridine in Escherichia coli tRNA^{Ser1} and
372 tRNA^{Tyr2} by 1H-15N two-dimensional NMR spectroscopy. *J Biol Chem* **261**, 12074-12078 (1986).
- 373 21 Horie, N. *et al.* Modified nucleosides in the first positions of the anticodons of tRNA(Leu)⁴ and
374 tRNA(Leu)⁵ from Escherichia coli. *Biochemistry* **38**, 207-217, doi:10.1021/bi981865g (1999).
- 375 22 Salazar, J. C., Ambrogelly, A., Crain, P. F., McCloskey, J. A. & Soll, D. A truncated aminoacyl-tRNA synthetase
376 modifies RNA. *Proc Natl Acad Sci U S A* **101**, 7536-7541, doi:10.1073/pnas.0401982101 (2004).
- 377 23 Bjork, G. R. & Hagervall, T. G. Transfer RNA Modification. *EcoSal Plus* **1**, doi:10.1128/ecosalplus.4.6.2
378 (2005).
- 379 24 Miyauchi, K., Kimura, S. & Suzuki, T. A cyclic form of N6-threonylcarbamoyladenine as a widely
380 distributed tRNA hypermodification. *Nat Chem Biol* **9**, 105-111, doi:10.1038/nchembio.1137 (2013).
- 381 25 Rodriguez-Hernandez, A. *et al.* Structural and mechanistic basis for enhanced translational efficiency by 2-
382 thiouridine at the tRNA anticodon wobble position. *J Mol Biol* **425**, 3888-3906,
383 doi:10.1016/j.jmb.2013.05.018 (2013).
- 384 26 Sakai, Y., Miyauchi, K., Kimura, S. & Suzuki, T. Biogenesis and growth phase-dependent alteration of 5-
385 methoxycarbonylmethoxyuridine in tRNA anticodons. *Nucleic Acids Res* **44**, 509-523,
386 doi:10.1093/nar/gkv1470 (2016).
- 387 27 Sakai, Y., Kimura, S. & Suzuki, T. Dual pathways of tRNA hydroxylation ensure efficient translation by
388 expanding decoding capability. *Nat Commun* **10**, 2858, doi:10.1038/s41467-019-10750-8 (2019).
- 389
390



391

392 **Figure 1. Profiling tRNA modifications in *V. cholerae* through tRNA-seq**


393 (A) Heatmaps of frequency of misincorporation (Left) and termination (Right)

394 in a representative tRNA sample isolated from stationary phase *V. cholerae* (total of three independent

395 samples). Positions of modifications bearing greater than 5 % of misincorporation or termination

396 frequency are shown; the identity of presumably shared modifications with *E. coli* are indicated in black

397 and the *V. cholerae*-specific signals are in white. Single nucleotide polymorphisms (SNPs) shown are
398 based on whole genome sequence of C6706¹⁸ (Supplementary Fig. 11) are also indicated in black.
399 (B) Schematic secondary structure of *V. cholerae* tRNAs showing sites of predicted tRNA modifications
400 deciphered from tRNA-seq data in (A). The positions and tRNA species in which the RT-derived
401 signatures are commonly observed in *E. coli* are shown in yellow. The positions and tRNA species that
402 have *V. cholerae* specific signals are colored coded as green (found in other organisms but not *E. coli*),
403 light blue (novel modifications/or editing) or pink (unknown).



404

405

Figure 2. Frequency of tRNA modification by acp^3U is dependent upon growth phase.

406

(A) Heatmap of misincorporation frequency at position 47 in *V. cholerae* tRNAs isolated from indicated growth condition. Signal intensities in each condition are the average values of three independent tRNA-seq datasets. tRNA species that showed significant differences between signals from log and stationary phase cells are colored in red (multiple two-sided t-test, FDR < 10 %).

410

(B) Secondary structure of tRNA-Met1 with modifications. RNase T₁ cleavage sites that form the fragment containing position 47 are indicated by red arrowheads.

412


(C) MALDI analysis (positive polarity mode measurements) of RNase A digests of tRNA-Met1 isolated from log and stationary phase samples. Nucleosides at position 47 are colored in red.

414

(D) Heatmap of misincorporation frequency at position 47 in *E. coli* tRNAs isolated from indicated.

415

growth condition. Signal intensities in each condition represent the values of one tRNA-seq dataset.



416

417


418

419

420

421

422 The fragments containing N387 are colored in red. The right panels show the secondary structures
423 containing modifications based on nucleoside and fragment analyses (Supplementary Fig. 7).
424 (B) Schematic of potential derivation of *acacp*³U (N387) from *acp*³U.
425 (C) MS/MS analyses of *acp*³U (upper panels) and N387 (lower panels). Left panels show the structures
426 and fragmentation patterns of the *acp*³U and *acacp*³U base components. Right panels show the product
427 ion spectra of *acp*³U in tRNA-Met1 (precursor ion; *m/z* 346) and N387 in tRNA-Glu (precursor ion; *m/z*
428 388). Fragment ions observed in *acp*³U are colored in blue and N387 specific fragment ions are colored
429 in red.
430 (D) Comparative genomic approach to identify an acetyltransferase required for *acacp*³U synthesis.
431 (E) *vc0317* is required for the acetylation of *acacp*³U. Nucleoside analyses detecting *acacp*³U (left) and
432 *acp*³U (right) in WT (upper) and $\Delta vc0317$ (lower) strains.
433 (F) Abundance of tRNA-Gln1A in WT and $\Delta vc0317$ strains. tRNAs were quantified through northern
434 blotting and normalized with the abundance of 5S rRNA; and average values, SD, and individual
435 biological replicates (WT; n = 5 and $\Delta vc0317$; n = 6) are shown as bars, error bars and circles,
436 respectively (p = 0.01, two-sided t-test).



437

438

Figure 4. Cytidine at position 32 in tRNA-Tyr undergoes C-to-U RNA editing.

439

(A) Sanger sequencing of cDNA of tRNA-Tyr from WT (top), $\Delta miaA$ (middle), and $\Delta thil$ (bottom) strains.

440

Position 32 is indicated by the arrow.

441

(B) Secondary structure of tRNA-Tyr with modifications based on fragment analyses (Supplementary

442

Fig. 12). s⁴U and i⁶A, which is a precursor of ms²io⁶A, are synthesized by *thil* and *miaA*, respectively.

443

RNase A cleavage sites that form the fragment containing position 32 are indicated by red arrowheads.

444

(C) Fragment analyses of an oligo protected portion (position 10 to 46) of tRNA-Tyr from WT (upper)

445

and $\Delta miaA$ (lower) strains. m/z values of detected peaks with assigned fragment sequences are shown.

446

The MALDI analyses were conducted in negative polarity mode.